Page 23 - RxExam's Naplex Theory Book Part 2

www.pharmacyexam.com Krisman

B). Interleukin Inhibitors

Dose Special Notes

Rilonacept Please Refer To Page 325 (Part 1) of Chapter 36-Rheumatoid Arthritis.

Tocilizumab Please Refer To Page 324 (Part 1) of Chapter 36-Rheumatoid Arthritis.

Anakinra Please Refer To Page 324 (Part 1) of Chapter 36-Rheumatoid Arthritis.

Canakinumab Please Refer To Page 325 (Part 1) of Chapter 36-Rheumatoid Arthritis.

Basiliximab 1. Renal 1). Basiliximab (Simulect) is a monoclonal antibody, produced by
(Injection) Transplant: recombinant DNA technology, that functions as an immunosuppressive
agent, specifically binding to and blocking the interleukin-2 receptors
a). 20 mg within 2 on the surface of activated T-lymphocytes.
hours prior to
transplantation. 2). Basiliximab (Simulect) is indicated for the prophylaxis of acute
organ rejection in patients receiving renal transplantation when used
b). Second 20 mg as part of an immunosuppressive regimen that includes cyclosporine
dose should be and corticosteroids.
given 4 days after
transplantation. 3). Basiliximab (Simulect) should only be administered via central or
peripheral IV administration only.

4). Severe acute hypersensitivity reactions including anaphylaxis, CMV
infections, nausea, vomiting, diarrhea and rash are also reported with
the therapy.

Daclizumab 1. Renal 1). Daclizumab (Zenapax) is a monoclonal antibody, produced by
(Injection) Transplant: recombinant DNA technology, that functions as an immunosuppressive
agent, specifically binding to and blocking the interleukin-2 receptors
Total: 5 doses on the surface of activated T-lymphocytes.

Dose: 1mg/kg 2). Daclizumab (Zenapax) is indicated for the prophylaxis of acute
organ rejection in patients receiving renal transplants. It is used as part
a). First dose 24 of an immunosuppressive regimen that includes cyclosporine and
hours before corticosteroids.
transplantation.
3). Daclizumab (Zenapax) should be administered via a peripheral or
b). Four remaining central vein over a 15-minute period.
doses at interval
of 14 days. 4). Hyperglycemia, severe acute hypersensitivity reactions including
anaphylaxis, infections including viral, fungal and bacterial, nausea,
vomiting, diarrhea and rash are also reported with the therapy.

22